Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T; APHINITY Steering Committee and Investigators. de Azambuja E, et al. Among authors: lambertini m. ESMO Open. 2023 Feb;8(1):100772. doi: 10.1016/j.esmoop.2022.100772. Epub 2023 Jan 19. ESMO Open. 2023. PMID: 36681013 Free PMC article. Clinical Trial.
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, Del Mastro L. Lambertini M, et al. Ann Oncol. 2015 Dec;26(12):2408-19. doi: 10.1093/annonc/mdv374. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347105 Free article. Review.
Twenty years of anti-HER2 therapy-associated cardiotoxicity.
Pondé NF, Lambertini M, de Azambuja E. Pondé NF, et al. Among authors: lambertini m. ESMO Open. 2016 Jul 21;1(4):e000073. doi: 10.1136/esmoopen-2016-000073. eCollection 2016. ESMO Open. 2016. PMID: 27843627 Free PMC article. Review.
Adjuvant trastuzumab: a 10-year overview of its benefit.
Lambertini M, Pondé NF, Solinas C, de Azambuja E. Lambertini M, et al. Expert Rev Anticancer Ther. 2017 Jan;17(1):61-74. doi: 10.1080/14737140.2017.1264876. Epub 2016 Dec 5. Expert Rev Anticancer Ther. 2017. PMID: 27883296 Review.
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M. Solinas C, et al. Among authors: lambertini m. Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Cancer Treat Rev. 2017. PMID: 28525810 Review.
Breast cancer treatment-induced cardiotoxicity.
Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Martel S, et al. Among authors: lambertini m. Expert Opin Drug Saf. 2017 Sep;16(9):1021-1038. doi: 10.1080/14740338.2017.1351541. Epub 2017 Jul 18. Expert Opin Drug Saf. 2017. PMID: 28697311 Review.
468 results